Answer
Dostarlimab is a humanised IgG4 monoclonal antibody that binds PD-1 receptors and blocks their interactions with PD-L1 and PD-L2, reactivating T-cell proliferation, cytokine production and cytotoxic activity and potentiating anti-tumour immune responses.
Sources for this answer
- JEMPERLI 500 mg concentrate for solution for infusionGlaxoSmithKline UK · emc · SmPC §5.1 Pharmacodynamic properties · Version 17Document updated
Sources checked